Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin & Natco Pharma Gets Final Approval for its ANDA for Bosentan Tablets
Details : Tracleer-Generic (bosentan) is an endothelin receptor antagonist small molecule drug candidate, which is indicated for the treatment of pulmonary arterial hypertension.
Product Name : Tracleer-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Receives Tentative Approval from The USFDA for Bosentan Tablets for Oral Suspension
Details : Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. It is developed for for the treatment of PAH in pediatric patients aged 3 years and older with idiopathic or congenial PAH to improve pulmonary vascular resistanc...
Product Name : Bosentan-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
February 15, 2023
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Reset All
